XML 107 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes
12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.
The components of the provision for income taxes are presented in the following table:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Current:
 
 
 
 
 
Federal
$
4,000

 
$

 
$

State
2,000

 

 

Foreign

 
2,170,000

 

 
6,000

 
2,170,000

 

Deferred:
 
 
 
 
 
Federal
(263,000
)
 

 


State

 

 

Foreign

 

 

 
(263,000
)
 

 

 
$
(257,000
)
 
$
2,170,000

 
$



The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a 21% statutory tax rate for December 31, 2019 and 2018, and 35% statutory tax rate for December 31, 2017, is as follows: 
 
Year Ended December 31,
 
2019
 
2018
 
2017
Income (benefit) taxes at statutory rates
$
(25,370,000
)
 
$
(19,908,000
)
 
$
(30,872,000
)
State income tax, net of federal benefit

 
(4,000
)
 
(4,000
)
Foreign income taxes

 
2,170,000

 

Change in valuation allowance
25,457,000

 
20,898,000

 
(20,965,000
)
Research and development tax credits
(3,838,000
)
 
(3,170,000
)
 
(3,456,000
)
Change in fair value of warrants

 
(76,000
)
 
(282,000
)
Stock-based compensation
1,114,000

 
1,094,000

 
2,332,000

Uncertain tax positions
1,537,000

 
1,268,000

 
846,000

Expired NOLs and credits
616,000

 
2,176,000

 
454,000

Limited NOLs and credits
(616,000
)
 
(2,176,000
)
 
(165,000
)
Change in tax rates
12,000

 

 
50,019,000

Other
831,000

 
(102,000
)
 
2,093,000

 
$
(257,000
)
 
$
2,170,000

 
$



The income tax benefit recorded during the year ended December 31, 2019 of $0.3 million is principally due to a requirement under Accounting Standards Codification ("ASC") 740, Accounting for Income Taxes, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.
Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2019 and 2018 are shown below:
 
As of December 31,
 
2019
 
2018
Deferred tax assets:
 
 
 
Capitalized research expense
$
6,300,000

 
$
7,408,000

NOL carryforwards
110,788,000

 
89,399,000

Research and development and other tax credits
11,737,000

 
9,432,000

Deferred revenue
1,506,000

 
985,000

Deferred rent

 
2,013,000

Stock-based compensation
3,255,000

 
3,408,000

Acquired intangibles
889,000

 
912,000

Derivative liability
1,852,000

 

Interest expense
1,122,000

 

Investment in affiliated entity
645,000

 

Lease liability
4,722,000

 

Other
2,413,000

 
2,693,000

 
145,229,000

 
116,250,000

Valuation allowance
(137,159,000
)
 
(115,007,000
)
Total deferred tax assets
8,070,000

 
1,243,000

Deferred tax liabilities:
 
 
 
Acquired intangibles
(160,000
)
 
(142,000
)
Investment in affiliated entity

 
(4,000
)
Right of use asset
(2,894,000
)
 

Note discount
(2,862,000
)
 

Convertible note
(1,381,000
)
 

Fixed assets
(805,000
)
 
(1,121,000
)
Net deferred tax liabilities
$
(32,000
)
 
$
(24,000
)


As of December 31, 2019, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $483.3 million, $68.6 million and $80.5 million, respectively, net of the net operating losses that will expire due to IRC Section 382 limitations. The federal net operating loss generated in 2018 and 2019 of $186.6 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal NOL carryforward began to expire in 2020, and the California and Pennsylvania NOL carryforwards will begin to expire in 2028 and 2021, respectively, unless previously utilized.
In addition, as of December 31, 2019, the Company had federal and state research and development (R&D) tax credit carryforwards of $17.3 million and $3.2 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.
Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):
Expiration Date:
Federal NOLs
 
State NOLs
 
Federal R&D
 
State R&D
 
 
 
 
 
 
 
 
2020
$
1.6

 
$

 
$

 
$

2021
2.3

 
0.3

 

 

2022
6.0

 
0.3

 

 

2023
4.5

 
0.4

 

 

2024 and thereafter
282.3

 
148.1

 
17.3

 

Indefinite
186.6

 

 

 
3.2

 
$
483.3

 
$
149.1

 
$
17.3

 
$
3.2



Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s NOL and R&D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section 382/383 analysis, regarding the limitation of NOL and R&D credit carryforwards as of December 31, 2019. As a result of the analysis, the Company estimates that approximately $10.6 million of tax benefits related to NOL and R&D carryforwards will expire unused. Accordingly, the related NOL and R&D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&D carryforwards.
The following table summarizes the activity related to the Company's unrecognized tax benefits:
 
Year ended December 31,
 
2019
 
2018
 
2017
Balance at beginning of the year
$
9,632,000

 
$
8,313,000

 
$
6,855,000

Increases related to current year tax positions
1,575,000

 
1,319,000

 
1,532,000

Increases (decreases) related to prior year tax positions
(3,000
)
 

 
(74,000
)
Balance at end of the year
$
11,204,000

 
$
9,632,000

 
$
8,313,000



The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $9.9 million, $8.3 million and $7.1 million as of December 31, 2019, 2018 and 2017, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.
The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2016 and state and local income tax examinations before 2015. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not currently under Internal Revenue Service (“IRS”), state or local tax examination.